PremiumCompany AnnouncementsBiomea Fusion Reports Promising Preclinical Study Results Biomea Fusion announces common stock, warrant offering, no amount given Biomea Fusion Stockholders Vote on Key Proposals PremiumThe FlyBiomea Fusion assumed with an Overweight at Piper Sandler Biomea Fusion Focuses on Core Programs in Q1 2025 Biomea Fusion price target lowered to $18 from $40 at H.C. Wainwright PremiumRatingsBuy Rating for Biomea Fusion’s Icovamenib: A Promising Breakthrough in Diabetes Treatment Biomea Fusion Appoints Interim CEO Amid Leadership Changes Biomea Fusion names Mick Hitchcock to succeed Thomas Butler as interim CEO 
